drugset / Trial / NCT03432741
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This pilot phase I trial studies the side effects of direct tumor microinjection and fludeoxyglucose F-18 positron emission tomography (FDG-PET) in testing drug sensitivity in patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or stage IV breast cancer that has returned after a period of improvement or does not respond to treatment. Injecting tiny amounts of anti-cancer drugs directly into tumors on the skin or in lymph nodes and diagnostic procedures, such as FDG-PET, may help to show which drugs work better in treating patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or breast cancer.
Timeline
- Start
- 2018-03-27
- Primary completion
- 2022-08-26
- Completion
- 2022-10-03
Outcome
Outcome not reported
Stopped (Business): “funding - sponsor filing Chapter 11 bankruptcy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belinostat | Small molecule | — | Other |
| Subject | Carfilzomib | Other / unclassified | — | Other |
| Subject | Copanlisib | Small molecule | — | Other |
| Subject | Daratumumab | Monoclonal antibody | — | Other |
| Subject | Gemcitabine | Small molecule | — | Other |
| Subject | Nivolumab | Monoclonal antibody | — | Other |
| Subject | Obinutuzumab | Monoclonal antibody | — | Other |
| Subject | Pembrolizumab | Monoclonal antibody | — | Other |
| Subject | Rituximab | Monoclonal antibody | — | Other |
| Subject | Romidepsin | Peptide | — | Other |
| Subject | Trastuzumab | Monoclonal antibody | — | Other |